Pharmacodynamic studies with a specific α2-adrenoceptor agonist (BHT-933) in man

Peter C. Rubin, Colin Howden, Kathleen McLean, John L. Reid

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We conducted pharmacodynamic studies in man with a specific α2-adrenoceptor agonist BHT-933. The study involved nine male normotensive volunteers each of whom received BHT-933 5 mg or placebo in random order. BHT-933 significantly lowered systolic and diastolic blood pressure (BP) in supine and standing positions, the greatest effect occurring 3-4 h following drug administration. Supine values: placebo 116/73; BHT-933 99/64. Standing values: placebo 114/79: BHT-933 92/67. Heart rate was uninfluenced by BHT-933 even at the time of maximum fall in BP. Plasma noradrenaline concentration in the supine position was significantly reduced: placebo 2.5 ± 0.8 nmol/L: BHT-933 1.7 ± 0.6. The haemodynamic changes accompanying Valsalva's manoeuvre and cold pressor test were uninfluenced by BHT-933. All subjects experienced sedation and dry mouth following BHT-933 with a time course similar to that of the fall in BP. These results are consistent with an effect of BHT-933 on BP control through an action on α2-receptors at the level of the brainstem.

Original languageEnglish (US)
Pages (from-to)527-530
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Volume4
Issue number4
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Adrenergic Receptors
Blood Pressure
Placebos
Supine Position
azepexole
Valsalva Maneuver
Posture
Brain Stem
Mouth
Volunteers
Norepinephrine
Heart Rate
Hemodynamics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacodynamic studies with a specific α2-adrenoceptor agonist (BHT-933) in man. / Rubin, Peter C.; Howden, Colin; McLean, Kathleen; Reid, John L.

In: Journal of Cardiovascular Pharmacology, Vol. 4, No. 4, 01.01.1982, p. 527-530.

Research output: Contribution to journalArticle

Rubin, Peter C. ; Howden, Colin ; McLean, Kathleen ; Reid, John L. / Pharmacodynamic studies with a specific α2-adrenoceptor agonist (BHT-933) in man. In: Journal of Cardiovascular Pharmacology. 1982 ; Vol. 4, No. 4. pp. 527-530.
@article{868e104872d14ae8a86e8163626ae594,
title = "Pharmacodynamic studies with a specific α2-adrenoceptor agonist (BHT-933) in man",
abstract = "We conducted pharmacodynamic studies in man with a specific α2-adrenoceptor agonist BHT-933. The study involved nine male normotensive volunteers each of whom received BHT-933 5 mg or placebo in random order. BHT-933 significantly lowered systolic and diastolic blood pressure (BP) in supine and standing positions, the greatest effect occurring 3-4 h following drug administration. Supine values: placebo 116/73; BHT-933 99/64. Standing values: placebo 114/79: BHT-933 92/67. Heart rate was uninfluenced by BHT-933 even at the time of maximum fall in BP. Plasma noradrenaline concentration in the supine position was significantly reduced: placebo 2.5 ± 0.8 nmol/L: BHT-933 1.7 ± 0.6. The haemodynamic changes accompanying Valsalva's manoeuvre and cold pressor test were uninfluenced by BHT-933. All subjects experienced sedation and dry mouth following BHT-933 with a time course similar to that of the fall in BP. These results are consistent with an effect of BHT-933 on BP control through an action on α2-receptors at the level of the brainstem.",
author = "Rubin, {Peter C.} and Colin Howden and Kathleen McLean and Reid, {John L.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1097/00005344-198207000-00001",
language = "English (US)",
volume = "4",
pages = "527--530",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Pharmacodynamic studies with a specific α2-adrenoceptor agonist (BHT-933) in man

AU - Rubin, Peter C.

AU - Howden, Colin

AU - McLean, Kathleen

AU - Reid, John L.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - We conducted pharmacodynamic studies in man with a specific α2-adrenoceptor agonist BHT-933. The study involved nine male normotensive volunteers each of whom received BHT-933 5 mg or placebo in random order. BHT-933 significantly lowered systolic and diastolic blood pressure (BP) in supine and standing positions, the greatest effect occurring 3-4 h following drug administration. Supine values: placebo 116/73; BHT-933 99/64. Standing values: placebo 114/79: BHT-933 92/67. Heart rate was uninfluenced by BHT-933 even at the time of maximum fall in BP. Plasma noradrenaline concentration in the supine position was significantly reduced: placebo 2.5 ± 0.8 nmol/L: BHT-933 1.7 ± 0.6. The haemodynamic changes accompanying Valsalva's manoeuvre and cold pressor test were uninfluenced by BHT-933. All subjects experienced sedation and dry mouth following BHT-933 with a time course similar to that of the fall in BP. These results are consistent with an effect of BHT-933 on BP control through an action on α2-receptors at the level of the brainstem.

AB - We conducted pharmacodynamic studies in man with a specific α2-adrenoceptor agonist BHT-933. The study involved nine male normotensive volunteers each of whom received BHT-933 5 mg or placebo in random order. BHT-933 significantly lowered systolic and diastolic blood pressure (BP) in supine and standing positions, the greatest effect occurring 3-4 h following drug administration. Supine values: placebo 116/73; BHT-933 99/64. Standing values: placebo 114/79: BHT-933 92/67. Heart rate was uninfluenced by BHT-933 even at the time of maximum fall in BP. Plasma noradrenaline concentration in the supine position was significantly reduced: placebo 2.5 ± 0.8 nmol/L: BHT-933 1.7 ± 0.6. The haemodynamic changes accompanying Valsalva's manoeuvre and cold pressor test were uninfluenced by BHT-933. All subjects experienced sedation and dry mouth following BHT-933 with a time course similar to that of the fall in BP. These results are consistent with an effect of BHT-933 on BP control through an action on α2-receptors at the level of the brainstem.

UR - http://www.scopus.com/inward/record.url?scp=0020030468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020030468&partnerID=8YFLogxK

U2 - 10.1097/00005344-198207000-00001

DO - 10.1097/00005344-198207000-00001

M3 - Article

VL - 4

SP - 527

EP - 530

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -